Loading...
OTCM
VXRT
Market cap132mUSD
Jul 09, Last price  
0.55USD
1D
-0.54%
1Q
-13.12%
Name

Vaxart Inc

Chart & Performance

D1W1MN
OTCM:VXRT chart
P/E
8.11
P/S
0.56
EPS
0.07
Div Yield, %
—
Shrs. gr., 5y
-13.92%
Rev. gr., 5y
125.76%
Revenues
237m
+726.68%
89,868,0000010,489,00035,005,00014,838,00033,600,00068,700,00024,600,0009,300,0008,900,0005,839,0004,159,0009,862,0004,046,000892,000107,0007,379,00028,700,000237,258,000
Net income
16m
P
-58,703,00047,069,000-18,738,000-18,727,000878,000-4,531,000-8,900,000-11,000,000-19,100,000-25,400,000-29,400,000-12,460,000-18,007,000-18,645,000-32,220,000-70,470,000-107,758,000-82,465,000-66,948,00016,327,000
CFO
8m
P
-43,912,000-26,744,000-18,901,0006,217,00039,932,000-15,166,000-13,900,000-3,300,000-9,600,000-14,100,000-30,000,000-10,040,000-14,548,000-13,090,000-23,750,000-59,832,000-94,779,000-70,453,000-44,764,0007,714,000
Dividend
Nov 09, 20121.108 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
URL
https://vaxart.com/
IPO date
Mar 17, 1980
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT